Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients
Qiu Jing Chen,Lin Lu,Wen Hui Peng,Jian Hu,Xiao Xiang Yan,Ling Jie Wang,Qi Zhang,Rui Yan Zhang,Wei Feng Shen
DOI: https://doi.org/10.1016/j.cca.2009.04.007
IF: 6.314
2009-01-01
Clinica Chimica Acta
Abstract:Results Genotype distribution and allele frequency of −1612 5A/6A MMP-3 and 3′UTR C/T TIMP-4 differed between patients with PP and those without in both diabetic and non-diabetic groups after Bonferroni's correction (all P < 0.0041667, except for allele frequency of MMP-3 [ P = 0.007] and genotype/allele frequency of TIMP-4 [ P = 0.04 and P = 0.016, respectively] in diabetes). MMP-3 and TIMP-4 polymorphisms were associated with changes in percent diameter stenosis and minimal lumen diameter in diabetic patients, and changes in cumulative coronary obstruction in both diabetic and non-diabetic patients (all P < 0.05). Multivariable regression analysis revealed that hypertension, low HDL-C and genotypes of MMP-3 and TIMP-4 were independent determinants of PP in the whole patients, with these 2 genetic factors being associated with PP in diabetic and non-diabetic subgroups. Conclusion This study demonstrated that MMP-3 and TIMP-4 polymorphisms affect angiographic coronary PP in type 2 diabetic and non-diabetic patients. Keywords Matrix metallopeptidase Tissue inhibitor of matrix metallopeptidase Polymorphism Plaque progression Diabetes mellitus 1 Introduction Atherosclerosis is characterized by a complex multi-factorial pathophysiology, in which genetic factor plays a role. Many studies have looked at the association between polymorphic variants in candidate genes and atherosclerosis. Matrix metalloproteinase (MMP) family consists of > 20 proteases, functioning to degrade collagens and other extracellular matrix proteins to maintain vascular homeostasis. Abnormal activities and expression of MMPs and TIMPs (tissue inhibitors of MMPs) have been implicated in the vascular remodeling and atherosclerosis [1] . Accumulating evidence suggests that several genetic variations of MMPs and TIMPs are predisposed to the development of atherosclerotic pathology, among which MMP-3 was associated with plaque progression (PP) [2–8] . Patients with diabetes display a substantially increased incidence of adverse cardiac events [9,10] . Intensified inflammatory reaction and impaired vascular homeostasis in diabetes have a direct influence on the formation and progression of atherosclerosis [11] . Moreover, previous studies have demonstrated significantly dysregulated expression and activities of major MMPs and TIMPs in vessel wall as well as in serum levels in diabetes, as compared to those in non-diabetes [12–17] . Thus, it is rational to evaluate the contribution of genetic variants in MMP-TIMP system to atherosclerosis progression separately, in diabetic or non-diabetic pathophysiological status. Until now, there has been a paucity of data regarding the relation between genetic variations of MMP-TIMP and atherosclerotic PP, especially in diabetic patients. As a preliminary study leading to a much larger evaluation of all intra-genic variation, in this study we assessed the relationship between 12 functional polymorphisms in MMP-1, -2, -3, -9, -10, -12, -13 and TIMP-1, -2, -3, -4 and angiographic PP at 1-year follow-up among non-diabetic and type 2 diabetic patients [2,18–25] , and compared baseline serum levels of MMP-1, -2, -3, -9, -10, -12, -13 and TIMP-1, -2, -3, -4 in patients with PP versus those without PP. 2 Methods 2.1 Patients Study participants were recruited from Shanghai Rui Jin Hospital Percutaneous Coronary Intervention (PCI) Outcome Program [26] , which aimed to estimate risk-adjusted outcomes in patients receiving PCI treatment. Data regarding demographics, clinical and angiographic features, and in-hospital management were collected retrospectively, whereas clinical and angiographic outcomes during follow-up were identified prospectively. A total of 976 consecutive patients with coronary artery disease underwent drug-eluting stent based PCI between October 2004 and December 2006. Excluded from the study were patients with acute myocardial infarction ( n = 72), severe heart failure with left ventricular ejection fraction < 30% ( n = 34), renal failure requiring dialysis ( n = 6), type 1 diabetes and serious life-threatening inflammation ( n = 28). For the purpose of this study, patients who died ( n = 21) or had no knowledge of repeat angiography during follow-up ( n = 255), and loss to follow-up ( n = 35) were also excluded from analysis. Another 26 patients were not included in this study because of symptom-driven repeat intervention and acute myocardial infarction undergoing primary PCI within 6 months of initial examination. The remaining 499 patients formed the study population, who had at least 1 stenotic lesion (luminal diameter narrowing > 20%) located at non-PCI intervened vessels on baseline coronary angiograms and received follow-up angiography at one year. The protocol was approved by the hospital Ethics Committee and written informed consent was obtained from all patients. 2.2 Coronary angiography and quantitative analysis Coronary arteriography and interventional procedures were performed by standard Judkins techniques or through radial approach [26] . Intracoronary injection of nitroglycerin (100 μg) was routinely made to avoid artery spasm. Coronary angiograms recorded at identical projections during initial and follow-up studies were used for quantitative coronary analyses (QCA, Centricity Cardiology CA 1000. v1.0, GE Healthcare, Piscataway, NJ). All imaging analyses were performed by 2 experienced interventional cardiologists, who were blind to patients' clinical data. Severity of coronary atherosclerosis was defined according to the numbers of coronary vessels with significant stenosis (angiographic luminal stenosis > 50%) as 1-, 2-, or 3-vessel disease. For lesion analysis, end-diastolic frames from both baseline and follow-up angiograms were selected with identical angulations that best showed the stenosis at its most severe degree with minimal foreshortening and branch overlap. Matching arterial segments were defined from the images acquired on the basis of the anatomic location of proximal and distal side branches. The coronary artery segments analyzed included all those plaques with a reference diameter ≥ 1.5 mm and a stenosis ≥ 20% at baseline and those with new lesions at follow-up in non-PCI artery. All coronary arteries intervened with PCI were excluded to avoid inclusion of post-PCI neointimal hyperplasia or restenosis. Using the outer diameter of the contrast-filled catheter as the calibration, the minimal lumen diameter (MLD) in diastole was measured from multiple projection; the results from the single “worst” view were recorded. The reference segment diameter was averaged from user-defined, 5-mm-long, angiographically normal segments proximal and distal to the lesion but between any major side branches. Atherosclerotic PP was defined as ≥ 1 lesion with decreased MLD ≥ 0.4 mm from baseline to follow-up angiography, a change representing approximately twice the SD for repeat measurements for lesions [27] , and occurrence of a new coronary lesion defined as a stenosis that was not apparent on the initial angiogram or was < 20% in diameter stenosis but that narrowed by ≥ 0.4 mm in MLD at the follow-up angiogram [28] . Cumulative coronary obstruction was the sum of all percent diameter stenoses in standard index unit (SI 50% = 0.50) [29,30] . Change of QCA measurement was defined as baseline QCA measurement minus follow-up measurement. All participants were grouped according to the presence or absence of coronary PP and of type 2 diabetes (fasting plasma glucose concentration ≥ 7.0 mmol/l and/or 2-h postprandial glucose level ≥ 11.1 mmol/l, taking anti-diabetic medications or receiving parenteral insulin treatment). 2.3 Biochemical assessment Blood samples were collected after overnight fasting and stored at − 80 °C. White blood cell count and serum levels of glucose and lipid profiles (total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], lipoprotein [Lp] (a) and triglycerides [TG] ) were measured (Hitachi 912 Analyzer, Roche Diagnostics, Germany). Serum levels of MMP-1, -2, -3, -9, -10, -12, -13 and TIMP-1, -2, -3, -4 were determined using commercially available ELISA kits (R & D Systems, Minneapolis, MN). The linear range was 0.08–125 ng/ml for MMP-1, -3, -13, 8–10,000 ng/ml for TIMP-4, 39–2500 pg/ml for MMP-10, -12, and 8–1000 ng/ml for other measurements. All ELISA measurements were taken in duplicate, and the intra-sample variation was < 10%, inter-assay CV was < 15%. 2.4 Polymerase chain reaction and genotyping Genome DNA was prepared with a DNA extraction kit (Qiagen, Valencia, CA), and stored at − 80 °C before use. Polymerase chain reaction (PCR) analysis was performed using genomic DNA as a template in a final reaction volume of 50 μl. Genotyping was determined by restriction fragment length polymorphism (RFLP) or by sequencing. Primer Express Software (ABI, Foster City, CA) was used to design primers ( Table 1 ). Briefly, in a final volume of 50 μl, PCR buffer, 10 pmol of forward and reverse primers, 2.5 units of Taq DNA polymerase (Promega, Madison WI), and 0.5 μg of template DNA were mixed. PCR condition was: denaturation at 94 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 60 s, annealing for 60 s, extension at 72 °C for 60 s, and final extension at 72 °C for 10 min. The restriction enzyme digestion maps were visualized on 2% agarose gels, stained with ethidium bromide. For PCR products which needed sequencing, the reaction mixture was purified using a commercially available PCR product purification kit (Promega), and sequencing was performed with ABI Prism 3700 DNA Analyzer (Applied Biosystems, Foster City, CA) to determine the polymorphisms. 2.5 Statistical analyses Continuous variables were expressed as mean ± SD, and categorical variables were presented as frequencies. Normal distribution was evaluated with Kolmolgorov–Smirnov test. Logarithmic transformation was performed on the continuous variables of non-normal distribution before statistical calculations. Comparisons between groups were made using unpaired t tests or ANOVA, when appropriate. Comparisons between baseline and follow-up were performed with paired t tests, and qualitative variables were compared using χ 2 test. Since 12 polymorphisms were evaluated to compare SNP frequencies between patients with PP and those without, Bonferroni's correction of P value was performed. Multivariate logistic regression model was constructed to assess the independent determinants of PP. A 2-sided probability level of ≤ 0.05 was considered significant. All analyses were done with SPSS for Windows 13.0 (SPSS Inc, Chicago, IL). 3 Results 3.1 Clinical characteristics and angiographic features Among a total of 499 patients (364 non-diabetic and 135 diabetic patients) in this study, PP occurred in 186 (51.1%) non-diabetic and 63 (46.7%) diabetic patients. Diabetic patients with PP did not differ significantly from those without PP regarding age, gender, cigarette smoking, kidney function test results and medical treatments, but hypertension and higher triglyceride were more prevalent in these patients with PP than in those without. Serum levels of HDL-C were lower in both diabetic and non-diabetic patients with PP ( Table 2 ). As expectation, diabetic patients displayed higher incidence of multi-vessel diseases. Dramatic changes in percent diameter stenosis, MLD and cumulative coronary obstruction were observed in the examined coronary arteries in both diabetic and non-diabetic patients with PP (all P < 0.001) ( Table 2 ). No obvious difference was observed in clinical characteristics between 255 patients without repeat angiography and initially excluded from analysis and those participating to this study (data not shown). 3.2 Genotype distribution and allele frequencies of MMPs and TIMPs The distributions of MMP and TIMP polymorphisms were consistent with Hardy–Weinberg equilibrium except for 180A/G MMP-10 (4 subjects with AG genotype, the others having GG genotype) and -82A/G MMP-12 (8 subjects with AG genotype, the others having AA genotype). Notably, significant difference in genotype distribution and allele frequency of -1612 5A/6A in MMP-3 were observed between patients with PP and those without in both diabetic and non-diabetic groups, with allele 6A being related to lesion progression after Bonferroni's correction of P value (all P < 0.004, except P = 0.007 for allele frequency difference). Patients carrying allele T at 3′UTR of TIMP-4 displayed marked PP in non-diabetic group ( P < 0.0041667) and obvious trend in diabetic group ( P = 0.016). -790 T/G MMP-2 demonstrated mild disparity in genotype distribution and high allele T frequency in patients with PP versus those with no PP in diabetic cohort ( P = 0.041 and P = 0.022). The other polymorphisms of MMPs and TIMPs examined did not show any association with PP in diabetic or non-diabetic patients ( Table 3 ). Serum levels of MMP-1, -2, -3, -9, -10, -12, -13 and TIMP-1, -2, -3, -4 did not differ between patient with PP and those without in both diabetic and non-diabetic groups (see supplemental Table ), neither did these levels correlate with genotypes of MMPs and TIMPs. 3.3 Relation between MMP and TIMP genotypes and change in QCA measurements Prominent difference in changes of MLD and cumulative coronary obstruction was observed among genotypes of MMP-2, -3 and TIMP-4 polymorphisms ( Table 4 ). Genotype 6A6A of -1612 5A/6A MMP-3 was associated with changes in percent diameter stenosis ( P = 0.028) and MLD ( P < 0.01) in diabetic group, and correlated with increased cumulative coronary obstruction in both diabetic and non-diabetic groups (all P < 0.01). Patients with genotype TT of -790G/T MMP-2 had apparent changes in these QCA measurements in diabetic group (all P < 0.05). In addition, genotype carrying allele T of TIMP-4 (3′UTR C/T) were related to cumulative coronary obstruction in non-diabetic and diabetic groups (both P < 0.01), and correlated with changes in percent diameter stenosis and MLD in diabetic group (both P < 0.01). However, the other examined polymorphisms of MMP-TIMP did not correlate with the QCA measurements. 3.4 Multivariable regression analysis Multivariable logistic regression analysis, including traditional cardiovascular risk factors and genetic variants ( Tables 2 and 3 ), revealed that hypertension, low HDL-C, genotype 6A/6A of MMP-3 polymorphism, and genotypes carrying allele T of TIMP-4 polymorphism were independently associated with PP in the whole patients. These two genetic factors persisted to be independent risk factors for PP in diabetic and non-diabetic groups, together with other risk factors ( Table 5 ). In addition, cumulative effects of MMP-3 (6A/6A) and TIMP-4 genotypes (CT and TT) were also observed in the whole ( P < 0.001) and diabetic patients ( P = 0.002), with obvious trend in non-diabetic patients ( P = 0.062) ( Table 6 ). 4 Discussion Accumulating data have indicated that MMP polymorphisms exert influence on the development of atherosclerosis [2–4] . MMP-TIMP system in vessel wall is substantially dysregulated in diabetes, jointly representing a critical but potentially unequal impact of genetic variations of MMP-TIMPs on coronary lesion progression in diabetes and non-diabetes [31] . This study demonstrated an association of MMP-3-1612 5A/6A with PP in both diabetic and non-diabetic patients, and for the first time, showed that genotypes carrying allele T of 3′UTR TIMP4 were related to PP in these patients. These two polymorphisms were associated with changes in percent diameter stenosis, MLD and cumulative coronary obstruction. Multivariable logistic regression analysis indicated that genotype 6A/6A MMP-3 and allele T carriers of TIMP-4 were independent determinants of PP after adjusting conventional risk factors, with prominent cumulative effect of these two genetic factors. Taken together, our results supported a hypothesis that genetic variations in MMP-TIMP family may affect coronary atherosclerotic PP in diabetes as well as in non-diabetes. MMP-3 has a proteolytic activity on a number of extracellular matrix proteins, ranging from collagen, proteoglycans, laminin, and elastin to gelatins. It can also activate several other MMPs. The 5A/6A polymorphism of MMP-3 is located within the interleukin-1 responsive element for several transcriptional regulators including NF-kB p50 homodimer [32] . In vitro experiments showed that 5A allele had increased activity in driving gene expression than 6A allele [32–34] . Patients with genotypes carrying allele 6A had a high rate of coronary artery disease and angiographic coronary atherosclerotic lesion growth [2–4] . Our findings were consistent with those results, and the associative effect was further extended from the field of non-diabetes to diabetes. In this study, the genotype and allele frequencies of 5A/6A polymorphism were comparable to those in a study exploring the same polymorphism in Chinese patients with myocardial infarction [35] . In addition, the frequencies of allele 6A in patients with PP (91.3% in diabetes and 89.2% in non-diabetes) were similar to those in patients with unstable angina (84%) reported by White et al. Likewise, patients without PP (78.5% in diabetes and 80.1% in non-diabetes) and those with stable angina (68%) in their study had close frequency of allele 6A [4] . TIMP-4 is expressed predominantly in the heart, which binds strongly to the carboxyl hemopexin domain of MMP-2 and inhibits the activation of MMP-2. Since 3′ UTR is involved in regulating gene expression at pre-mRNA level, genetic variations in cis -elements of 3′UTR may affect 3′UTR formation, polyadenylation, mRNA stability and regulation of gene expression. C/T 3′UTR TIMP-4 polymorphisms produce alterations in mRNA stem-loop structure, which is critical for regulation of mRNA stability and translation [36] . Our study is the first to show that this polymorphism was related to PP in non-diabetic and diabetic patients. Moreover, the allele T frequency in patients with PP (20.5%) was similar to that in patients with arthritis (25.2%), as compared to those in controls (11.6% and 13.7%, respectively), in a study investigating the relation of TIMP-4 polymorphism and arthritis occurrence [36] . Nevertheless, this associative effect in our study was weak in diabetes, which may be explained, at least partly, by the small number of diabetic patients. Difference in genotype and allele frequency of MMP-2-790T/G polymorphism was also a novel finding in diabetic patients with PP versus those without. However, multivariable analysis did not support the association after adjusting conventional risk factors. Previous studies noted that this polymorphism was associated with coronary triple vessel disease [37] . Bioinformatic analysis suggested that allele T sequence allowed a direct binding of three transcription factors, but not G variant of MMP-2-790 T/G polymorphism. The reason for the absence of associative effect in non-diabetic patients remains unknown as there was no direct evidence explaining the molecular function of this polymorphism. In this study, serum concentrations of MMP-1, -2, -3, -9, -10, -12, -13 and TIMP-1, -2, -3, -4 did not differ significantly between patients with PP and those without in both diabetic and non-diabetic groups. This may be mainly due to predominant usage of anti-atherosclerotic agents including statins. However, the possibility that genetic polymorphisms may affect tissue levels could not be excluded simply by measuring plasma MMP levels alone. Finally, we combined the diabetic and non-diabetic patients, and grouped them based upon coronary PP. Logistic regression analysis showed that diabetes was not an independent determinant of PP. This could be partially caused by the composition of recruited patients in our study. 5 Limitation There were several limitations for our study. First, the sample size of diabetic group was relatively small, but the associative effect could be statistically identified with the current number of subjects. Nevertheless, a large-scale prospective study should be launched to confirm the associative effect of these polymorphisms with PP. Second, we analyzed only one polymorphism in most of the genes, which could have missed an association that was to a specific polymorphism. However, this study benefited from a prospective recruitment and from a candidate gene approach. We selected 11 genes of MMP-TIMP family on the basis of their relevance in the pathophysiology of coronary atherosclerotic progression, and major polymorphisms selected for this study were functional and were implicated in disease occurrence. 6 Conclusion The present study has demonstrated that polymorphisms of MMP-3 and TIMP-4 affect angiographic coronary PP in non-diabetic and type 2 diabetic patients. Determination of frequent population polymorphisms in MMP-TIMP genes and evaluation of genotype risks for multigenic coronary atherosclerotic progression may be fundamental for individual therapy. Acknowledgement This work was supported by the Shanghai Municipal Foundation for Science and Technology. Appendix A Supplementary data Appendix A Supplementary data Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.cca.2009.04.007 . References [1] Z.S. Galis J.J. Khatri Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ Res 90 2002 251 262 [2] S. Ye G.F. Watts S. Mandalia S.E. Humphries A.M. Henney Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis Br Heart J 73 1995 209 215 [3] S.E. Humphries L.A. Luong P.J. Talmud The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study Atherosclerosis 139 1998 49 56 [4] A.J. White S.J. Duffy A.S. Walton Matrix metalloproteinase-3 and coronary remodeling: implications for unstable coronary disease Cardiovasc Res 75 2007 813 820 [5] S. Ye C.R. Gale C.N. Martyn Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease Eur Heart J 24 2003 1668 1671 [6] T. Nojiri H. Morita Y. Imai Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese Int J Cardiol 92 2003 181 186 [7] S. Beyzade S. Zhang Y.K. Wong I.N. Day P. Eriksson S. Ye Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction J Am Coll Cardiol 41 2003 2130 2137 [8] D. Krex H. Rohl I.R. Konig A. Ziegler H.K. Schackert G. Schackert Tissue inhibitor of metalloproteinases-1, -2, and -3 polymorphisms in a white population with intracranial aneurysms Stroke 34 2003 2817 2821 [9] R. Huxley F. Barzi M. Woodward Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies BMJ 332 2006 73 78 [10] A. Sjoholm T. Nystrom Inflammation and the etiology of type 2 diabetes Diabetes Metab Res Rev 22 2006 4 10 [11] P.J. Boyle Diabetes mellitus and macrovascular disease: mechanisms and mediators Am J Med 120 2007 S12 S17 [12] A.W. Chung A.D. Booth C. Rose C.R. Thompson A. Levin C. van Breemen Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction J Vasc Res 45 2008 357 362 [13] G. Derosa A. D'Angelo C. Tinelli Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects Diabetes Metab 33 2007 129 134 [14] A.W. Chung Y.N. Hsiang L.A. Matzke B.M. McManus C. van Breemen E.B. Okon Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature Circ Res 99 2006 140 148 [15] A.W. Chung H. Luo T. Tejerina C. van Breemen E.B. Okon Enhanced cell cycle entry and mitogen-activated protein kinase-signaling and downregulation of matrix metalloproteinase-1 and -3 in human diabetic arterial vasculature Atherosclerosis 195 2007 e1 e8 [16] M.H. Tayebjee G.Y. Lip R.J. MacFadyen What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus? Diabet Med 22 2005 1628 1635 [17] L. Lu Q. Zhang L.J. Pu Dysregulation of matrix metalloproteinases and their tissue inhibitors is related to abnormality of left ventricular geometry and function in streptozotocin-induced diabetic minipigs Int J Exp Pathol 89 2008 125 137 [18] J.L. Rutter T.I. Mitchell G. Buttice A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription Cancer Res 58 1998 5321 5325 [19] S.J. Price D.R. Greaves H. Watkins Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation J Biol Chem 276 2001 7549 7558 [20] B. Zhang S. Ye S.M. Herrmann Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis Circulation 99 1999 1788 1794 [21] S. Jormsjo S. Ye J. Moritz Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease Circ Res 86 2000 998 1003 [22] S. Yoon H. Kuivaniemi Z. Gatalica MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black male subjects Matrix Biol 21 2002 487 498 [23] X. Wang G. Tromp C.W. Cole Analysis of coding sequences for tissue inhibitor of metalloproteinase 1(TIMP1) and 2 (TIMP2) in patients with aneurysms Matrix Biol 18 1999 121 124 [24] M. Beranek K. Kankova J. Muzik Identification of novel common polymorphisms in the promoter region of the TIMP-3 gene in Czech population Mol Cell Probes 14 2000 265 268 [25] H.S. Kang S.K. Kim B.K. Cho Y.Y. Kim Y.S. Hwang K.C. Wang Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease Neurosurgery 58 2006 1074 1080 [26] R.Y. Zhang Z.B. Zhu Q. Zhang Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention Int J Cardiol 2008 [Electronic publication ahead of print] [27] D. Waters J. Lesperance T.E. Craven G. Hudon L.D. Gillam Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials Circulation 87 1993 II38 II47 [28] C. Berry P.L. L'Allier J. Gregoire Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression Circulation 115 2007 1851 1857 [29] B.C. Solymoss M.G. Bourassa L. Campeau Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity Am J Cardiol 93 2004 159 164 [30] D. Waters L. Higginson P. Gladstone Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial Circulation 89 1994 959 968 [31] R. Marfella M. D'Amico K. Esposito The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment Diabetes 55 2006 622 632 [32] R.C. Borghaei P.L. Rawlings Jr M. Javadi J. Woloshin NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter Biochem Biophys Res Commun 316 2004 182 188 [33] S. Ye P. Eriksson A. Hamsten M. Kurkinen S.E. Humphries A.M. Henney Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression J Biol Chem 271 1996 13055 13060 [34] T.L. Medley B.A. Kingwell C.D. Gatzka P. Pillay T.J. Cole Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression Circ Res 92 2003 1254 1261 [35] X. Zhou J. Huang J. Chen S. Su R. Chen D. Gu Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study Thromb Haemost 92 2004 867 873 [36] H.J. Lee G.H. Lee S. Nah Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population Rheumatol Int 28 2008 845 850 [37] A. Vasku M. Goldbergova L. Izakovicova Holla A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790 T/G and -735C/T) is associated with coronary triple-vessel disease Matrix Biology 22 2004 585 591